Immunotherapy for genitourinary cancer in the elderly
In the following interview, Dr Bradley McGregor, a medical oncologist [...]
Anlotinib versus sunitinib as first-line treatment for metastatic kidney cancer
The results of a recent phase 2 study to evaluate [...]
Computer-designed interleukin 2 (IL 2) without the side effects?
Interleukin-2 (IL2) is a naturally-occurring biological therapy called a cytokine. [...]
Nivolumab is safe and effective for older kidney cancer patients
Findings from an expanded access programme giving 389 metastatic renal [...]
Managing adverse events for cancer immunotherapies
Immunotherapy treatments for cancer hold great promise, but also come [...]
Managing side effects of cabozantinib treatment for metastatic renal cell carcinoma
In this short but informative video Dr Laurence Albiges, from [...]
Cancer Drugs Fund has “not delivered meaningful value to patients or society”
A recent study published in the Annals of Oncology and carried [...]
Under-reporting immunotherapy-related side-effects is a concern in kidney cancer
In an interview with OncLive at the 2016 Kidney Cancer [...]
Side effects to mTOR drugs could be used as biological markers of efficacy in kidney cancer
A recent study published online in BioMed Central Cancer shows [...]
Immune system can attack organs after being unleashed by cancer drugs
Immunotherapy drugs have been hailed as a breakthrough in cancer [...]
